Key result
Left ventricular dysfunction was significantly associated with ventricular fibrillation during antiarrhythmic therapy, with lower ejection fractions in cases than controls (0.29 vs. 0.43; P<0.0001).
Why the study?
What clinical characteristics predispose patients to newly occurring ventricular fibrillation during antiarrhythmic drug therapy?
Population
90 patients treated for ventricular arrhythmias, including 28 patients with newly occurring ventricular…
Comparison
Single-drug antiarrhythmic therapy in patients… vs Control group of 62 patients treated similarly…
Design
Case-control
Follow-up
mean 18 months
Authors
Loading...
LV dysfunction may heighten proarrhythmic risk during antiarrhythmic therapy; leaves open whether EF thresholds should guide selection or monitoring.
Case-Control (n=88)
What clinical characteristics predispose patients to newly occurring ventricular fibrillation during antiarrhythmic drug therapy?
Absolute Event Rate: 0.29% vs 0.43%
p-value: p=<0.0001
Left ventricular dysfunction, prolonged baseline QTc, and concomitant use of digitalis and diuretics predispose patients to early drug-associated ventricular fibrillation during antiarrhythmic therapy.
Minardo et al. (1988) conducted a case-control in Ventricular fibrillation during antiarrhythmic drug therapy (n=88). Antiarrhythmic drug therapy (quinidine, procainamide, or disopyramide) vs. Patients treated similarly for ventricular arrhythmias without ventricular fibrillation was evaluated on Left ventricular ejection fraction (p=<0.0001). Left ventricular dysfunction was significantly associated with ventricular fibrillation during antiarrhythmic therapy, with lower ejection fractions in cases than controls (0.29 vs. 0.43; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: